Why a Biologic and a JAK Inhibitor Can Share the Same Eczema Grade

A "strong recommendation" in the 2024 American Academy of Dermatology (AAD) guideline on systemic atopic dermatitis treatment tells you that a workgroup was confident the benefits outweigh the harms for most eligible adults. It does not tell you the drugs so labeled are equally safe. That single distinction explains why the guideline can place a monoclonal antibody and an oral Janus kinase (JAK) inhibitor side by side in its top tier while the FDA reserves a class boxed warning for the JAK inhibitors alone.

Key points#

• The 2024 AAD guideline gives its strong recommendation to five agents: the biologics dupilumab and tralokinumab, and the oral JAK inhibitors abrocitinib, baricitinib, and upadacitinib.
• A strong recommendation grades the balance of benefit and harm across a population, not the absence of risk and not a head-to-head safety ranking.
• The oral JAK inhibitors carry an FDA class boxed warning; the two biologics do not.
• Same grade, different monitoring: biologics usually need no routine bloodwork, while JAK inhibitors call for baseline and periodic labs and attention to age and cardiovascular and cancer risk.

Start with the drug that was never in the trial#

A useful way into this topic is a small puzzle. Two of the JAK inhibitors used for eczema, abrocitinib and upadacitinib, were never studied in the trial that triggered their strongest safety warning. Yet they carry the warning anyway. Holding that fact in mind makes the rest of the guideline easier to read, because it forces apart two things that look like one: how well a drug works for a defined group, and how cautious the label tells you to be about serious, uncommon harms.

The trial in question was ORAL Surveillance, a large randomized study of the JAK inhibitor tofacitinib compared against tumor necrosis factor (TNF) inhibitors. It enrolled rheumatoid arthritis patients aged fifty and older who had at least one cardiovascular risk factor. Tofacitinib did not meet the bar for non-inferiority on major adverse cardiovascular events or on cancer, and the data pointed to more blood clots and more deaths. In September 2021 the FDA responded with a class boxed warning spanning serious infections, mortality, major cardiovascular events, malignancy, and thrombosis, and it narrowed the affected labels so the drugs are held for patients who could not tolerate or did not respond to TNF blockers. Abrocitinib and upadacitinib inherited that warning by mechanism and by drug class, not because either was tested in that trial.

What the grade is actually measuring#

The AAD guideline, published in the Journal of the American Academy of Dermatology (online late 2023, in print early 2024), updated the prior systemic-therapy guidance and issued its recommendations using the GRADE method. GRADE keeps two ideas separate that ordinary reading tends to blur together.

The first is the strength of a recommendation. "Strong" means the panel judged that the good effects clearly outweigh the bad ones for nearly everyone who qualifies. "Conditional" means it is a closer call that leans more on the individual patient's situation and preferences.

The second is the certainty of the evidence, rated high, moderate, or low, which is really a statement about how much the estimate might move as new studies arrive. Because these axes are independent, a drug can be strongly recommended and still carry real risk. The grade summarizes a trade-off; it does not promise that the downside is small.

Where each therapy landed#

Under that framework, all five newer agents, dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib, earned strong recommendations for adults with moderate-to-severe disease. The older systemic options were graded more cautiously. Phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate received conditional recommendations in their favor, and the guideline recommends against routine use of systemic corticosteroids.

Two design choices in the guideline are easy to overlook. First, each therapy is graded against its own body of evidence rather than slotted into a single ranked ladder, so a shared "strong" label does not make the five agents interchangeable. Second, the recommendations follow the evidence rather than the regulatory paperwork: baricitinib was strongly recommended for atopic dermatitis even though its U.S. approvals sit in other conditions. A specialty-society recommendation and an FDA label are different instruments answering different questions.

Same grade, different harm profile#

This is why "strong recommendation" and "boxed warning" can describe the very same drug without contradiction. They live on separate axes. The recommendation answers a population question: on average, for eligible adults, does benefit beat harm? The boxed warning answers a regulatory question: are there serious, if infrequent, risks that demand heightened caution and, for some patients, rule the drug out?

Dupilumab and tralokinumab block interleukin signaling rather than JAK pathways, and they carry no boxed warning. The eczema JAK inhibitors carry the class warning in full, and their approvals reserve them for disease not adequately controlled by other systemic drugs, including biologics, or where those options are not advisable. So an identical grade rests on genuinely different safety pictures, and the guideline never claimed otherwise.

Where the difference shows up in practice#

The gap between the two axes becomes concrete at the point of monitoring. Dupilumab and tralokinumab generally need no routine laboratory surveillance. The oral JAK inhibitors call for baseline and periodic bloodwork and for ongoing attention to age, cardiovascular history, cancer risk, and prior treatment. None of that lives inside the two words "strong recommendation," which is exactly why the phrase is a starting point and not a verdict.

A guideline grade is a synthesis of group-level evidence built to orient a clinician and an informed patient. It cannot weigh one person's other conditions, values, and treatment history, and that weighing is the step that turns a recommendation into an actual decision. Read this way, the 2024 guideline is internally consistent. It can seat a biologic and a JAK inhibitor in the same tier because both clear the bar of confident net benefit for the eligible population, while still expecting the boxed warning, the monitoring burden, and each patient's risk factors to decide which agent, if any, is used.